Although many tracers have been developed to aid in the diagnosis and treatment of AD, including those targeting tau, P2X7, phosphodiesterase PDE10A, and synaptic vesicle glycoprotein 2A (McCluskey et al., 2020), only few RAGE-targeting imaging tracers are currently available apart from [18F]-FPS-ZM1, and they all have certain limitations in the diagnosis of AD. This evidence concerns the gene MAPT and Alzheimer disease.